Incidence and survival of adult cancer patients in Taiwan, 2002–2012

Chiang, Chun‐Ju; Lo, Wei Cheng; Yang, Yu‐Cih; You, San–Lin; Chen, Chien Jen; Lai, Ming-Yang

doi:10.1016/j.jfma.2015.10.011

Cited by 218 publications

(191 citation statements)

References 18 publications

Supporting

Mentioning

182

Contrasting

Order By: Relevance

“…In the US, approximately 16,910 new cases of esophageal cancer were diagnosed in 2016, and 15,690 deaths were estimated (1)(2)(3). Prognosis of esophageal cancer has been dismal regardless of the aggressive treatments, partly owing to the late diagnosis of this disease.…”

Section: Introductionmentioning

confidence: 99%

The frontline of esophageal cancer treatment: questions to be asked and answered

Tu¹,

Hsu²

2018

Ann. Transl. Med.

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The frontline of esophageal cancer treatment: questions to be asked and answered

Tu¹,

Hsu²

2018

Ann. Transl. Med.

View full text Add to dashboard Cite

“…The hospitals with a capacity of >50 beds must participate in the TCRD. In 2012, the completeness of the TCRD was 98.4%, and 91.5% of the incident cases had histological or cytological verifications for the diagnosis of cancers 22, 23, 24. In addition, the National Health Insurance (NHI) system in Taiwan is a mandatory and single‐payer health insurance system, which has been operated by the government from 1995.…”

Section: Introductionmentioning

confidence: 99%

Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real‐world analysis from Taiwan Cancer Registry Database

et al. 2018

View full text Add to dashboard Cite

Follicular lymphoma (FL) is the most frequent indolent lymphoma in Western countries, but it is less frequent in Asia. Several trials have demonstrated the progression‐free benefit of rituximab maintenance for FL patients in Western countries. However, the overall survival (OS) benefits and effectiveness of rituximab maintenance in Asian FL patients remain uncertain. We utilized the Taiwan Cancer Registry Database and the National Health Insurance Research Database to investigate the roles of rituximab maintenance for newly diagnosed FL patients in Taiwan. Among 836 patients with newly diagnosed FL during 2009‐2012, we enrolled patients with stage II‐IV diseases receiving 4‐8 cycles of rituximab‐containing induction chemotherapies (R‐induction). We excluded those who died or received additional chemotherapy within 180 days after R‐induction. Among the 396 enrolled patients, 260 underwent rituximab maintenance (R‐maintenance group), and 136 served as the observation group. The R‐maintenance group received less anthracycline and fewer cycles of R‐induction than the observation group, but they exhibited a significantly better OS both in the univariate and multivariate analyses [hazard ratio, 0.42; 95% confidence interval, 0.19‐0.91] after adjusting for age, sex, and Ann Arbor stages. Meanwhile, we also found more patients required further therapies in the first 6 months after the cease of rituximab maintenance. In the subgroup analysis, patients older than 60 years or with stage IV diseases benefited more from rituximab maintenance. Conclusively, our nationwide study is the first one to demonstrate the OS benefit of rituximab maintenance after induction therapies in newly diagnosed FL patients from Asian populations.

show abstract

“…A recent study reported prevalence and incidence trends of multiple categories of cancer in Taiwan using the National Cancer Registry Database [11]. However, stratification of the estimates and mortality trends of breast cancer are lacking.…”

Section: Introductionmentioning

confidence: 99%

Epidemiology and survival outcome of breast cancer in a nationwide study

et al. 2017

View full text Add to dashboard Cite

Breast cancer is among the most prevalent cancers in Taiwan. The National Health Insurance database was used to identify patients with breast cancer and estimate the yearly prevalence and incidence of breast cancer between 1997 and 2013. Joinpoint regression analysis was used for the annual percentage change of incidence, prevalence, and survival outcome. Among 12,181,919 female beneficiaries in 2013, the prevalence was 834.37 per 100,000 persons (95% confidence interval, 829.28–839.45) and the incidence was 93.00 per 100,000 person-year (95% confidence interval, 91.27–94.73). The average annual percentage change of the age-standardized breast cancer incidence was 3.5 per 100,000 person-years (3.1–3.8; P < 0.05), suggesting an increase in breast cancer incidence over the study period. The 5-year mortality rate was 4.5% in 1997 and 4.4% in 2008. The 5-year mortality rate among patients with Charlson comorbidity index > 1 was 39.1% (19.2%–59.1%) in 1997 and 21.1% (15.7%-32.0%) in 2008, with an annual percentage change of –0.8 (–1.3 to 2.9), suggesting that the mortality rate was gradually decreasing in patients with comorbidities. In conclusion, 1 in 120 women in Taiwan has breast cancer and the incidence is rising, while the annual percentage change of breast cancer prevalence is decreasing. The mortality rate of breast cancer was essentially stable, but the 1-year, 2-year, and 5-year mortality rates in people with Charlson comorbidity index > 1 were declined.

show abstract

Incidence and survival of adult cancer patients in Taiwan, 2002–2012

Abstract: Our study showed increased incidence in most cancers and provided baseline estimates of stage-specific RSRs among the Taiwanese adult population. Continuous surveillance may help politicians to improve health policies and cancer care in Taiwan.

Cited by 218 publications

References 18 publications

The frontline of esophageal cancer treatment: questions to be asked and answered

The frontline of esophageal cancer treatment: questions to be asked and answered

Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real‐world analysis from Taiwan Cancer Registry Database

Epidemiology and survival outcome of breast cancer in a nationwide study

Contact Info

Product

Resources

About